 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
ISTA PHARMACTLS, (ISTA) Stock Rating Learn More
| Our Overall Rating on ISTA PHARMACTLS, ISTA is Not Available | | ISTA Pharmaceuticals, Inc. engages in the development and commercialization of products for serious diseases and conditions of the eye. Its product pipeline includes Vitrase, a proprietary formulation of ovine hyaluronidase for the treatment of vitreous hemorrhage, for use as a spreading agent to facilitate the absorption and dispersion of other injected drugs, as well as for the treatment of diabetic retinopathy; Istalol, a topical solution of timolol, for the treatment of glaucoma, a chronic disease that gradually reduces eyesight; Xibrom, a topical nonsteroidal anti-inflammatory compound for the treatment of ocular inflammation; and Caprogel, a topical gel formulation of aminocaproic acid, for the treatment of hyphema. ISTA Pharmaceuticals has collaborations with Allergan, Inc.; Otsuka Pharmaceutical Co., Ltd.; Senju Pharmaceuticals Co., Ltd.; and Eastern Virginia Medical School. The company was founded in 1992 as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in 2000. ISTA Pharmaceuticals is headquartered in Irvine, California. | | Our Not Available Rating on ISTA was issued on 11/21/2008 |
ISTA PHARMACTLS Technical Rating
|
|
|
|
